Caco-2 Cell Permeability Assay Protocol for Drug Absorption

The Biopharmaceutics Classification System (BCS), officially adopted by the FDA in 2000, categorizes drugs into four classes based on their solubility and intestinal permeability, enabling biowavers that replace clinical bioequivalence studies with in vitro testing for certain drug products; class 1 drugs (highly soluble and highly permeable) are most likely to qualify for biowavers because their absorption is predictable and consistent across patients, while permeability assessment requires comparing test compounds against validated reference standards using models like Caco-2 cell monolayers to determine if they meet the 90% oral absorption threshold.

The Biopharmaceutics Classification System (BCS) predicts drug absorption based on solubility and permeability, classifying drugs into four categories: Class 1 (highly soluble, high permeability), Class 2 (poorly soluble, high permeability), Class 3 (highly soluble, low permeability), and Class 4 (poorly soluble, low permeability). Regulatory agencies including EU, EAEU, and USA permit BCS-based waivers for Class 1 and Class 3 drugs when criteria are met: rapid dissolution (>85% in 30 minutes), wide therapeutic index, and similar excipient composition. The scientific rationale is that if dissolution occurs faster than gastric emptying, absorption becomes independent of dissolution. Permeability assessment requires clinical pharmacokinetic studies using material balance methods, intestinal perfusion, or in vitro ex vivo methods like Caco-2 cell monolayers. For Class 2 and Class 4 drugs, absorption is permeability-limited, so rapid dissolution (>85% in 15 minutes) enables waivers. Documentation requires justifying that literature data applies to the specific product, with careful testing conditions to avoid false conclusions.

BCS-based bioequivalence waivers provide opportunities to avoid clinical studies for generic drugs through four pillars: solubility, permeability, dissolution (85% in 15 min for class 3), and excipient similarity. The framework evolved from Supac guidance (1997) to ICH M9 (2021). A risk-based classification system categorizes BCS class 3 drugs into low, medium, and high risk based on transport mechanisms, excipient differences, and PK variability. PBPK/PBBM integrates physicochemical, pharmacokinetic, and physiological data to predict drug absorption. For BCS class 3 drugs where permeability governs absorption, dissolution criteria can be relaxed to 85% in 60 minutes. Model development requires systematic methodology: baseline model development using IV and oral data; extensive validation against literature and in-house studies; prediction error analysis (<10% acceptable); virtual bioequivalence simulations; establishing dissolution/permeability safe spaces. A case study demonstrated leveraging bioequivalence studies across markets where dissolution dissimilarity (F2 < 50 in pH 6.8) initially rejected waivers, but PBPK modeling showed dissolution differences didn't translate to bioequivalence failures, enabling approval despite failing traditional criteria.

The Biopharmaceutical Classification System (BCS), developed by Amidon and colleagues, classifies drugs into four categories based on solubility and permeability: Class 1 (high solubility, high permeability - well absorbed, e.g., diltiazem); Class 2 (low solubility, high permeability - absorption variable, e.g., griseofulvin); Class 3 (high solubility, low permeability - absorption variable, e.g., insulin); Class 4 (low solubility, low permeability - poorly absorbed, e.g., paclitaxel). This classification helps predict drug absorption behavior and guide formulation strategies.

The Biopharmaceutical Classification System (BCS) categorizes drugs into four classes based on two key physicochemical properties: solubility (whether a drug dissolves in 250 mL or less of water) and intestinal permeability (whether more than 90% of the administered dose is absorbed). Class I drugs have both high solubility and high permeability, Class II have high solubility but low permeability, Class III have low solubility but high permeability, and Class IV have both low solubility and low permeability. This classification system is essential for predicting drug absorption behavior, guiding formulation strategies, and determining eligibility for biowaivers in regulatory submissions.

This section presents the comprehensive characterization of the developed intestinal model incorporating epithelium, mucus-producing cells, ECM, and endothelium. Morphological investigations used acridine orange staining to visualize the mucus layer produced by HT29-MTX cells, confirming confluent mucus coverage. Tight junctions enabling cell signaling and barrier function were visualized using immunohistochemical staining for occludin protein via confocal laser scanning microscopy, revealing characteristic microvilli structures. Cell differentiation was assessed through alkaline phosphatase (ALP) release measurement, achieving 19.5% ALP activity compared to monoculture after 14 days, demonstrating functional brush border enzyme expression. The model achieved full characterization within two weeks versus the standard three-week cultivation period for conventional models.

Gut-on-a-chip models can develop mucus layers that can be manipulated to study their role in intestinal defense. Different compounds can stimulate or inhibit mucus development, allowing researchers to investigate how mucus barrier function interacts with microbiome colonization and disease progression. This capability extends the utility of these models for studying both protective and pathological aspects of intestinal physiology.

Multiple in vitro models replicate intestinal barrier function for research purposes. Caco-2 cells, derived from human colorectal carcinoma, form polarized monolayers with tight junctions when grown in transwell plates for 21 days, with trans-epithelial electrical resistance exceeding 500 ohms·cm² indicating proper barrier formation. Modern models combine Caco-2 cells with HT-29 goblet cells (ratio 3:1 to 9:1) to incorporate mucus production. Alternative approaches include Ussing chambers for immediate ex vivo tissue application and intestinal organoids derived from crypts that self-organize into mini-guts over seven days. Each model has specific applications: Caco-2/HT-29 co-cultures enable comparison with existing literature, while IPEC-J2 cells better represent immune responses. The choice depends on research objectives, with no single model being universally optimal.

Beyond simple Caco-2 models, more complex intestinal models can be created by adding bacteria (active or inactive), immune cells, cytokines, and multiple cell types. An example is an IBD model co-culturing Caco-2 cells with mucus-producing HT-29 cells and all immune components. This complexity allows researchers to study disease mechanisms and therapeutic interventions in more realistic contexts, moving from simple barrier studies to comprehensive disease modeling.

Primary gut models derived from human jejunal crypt stem cells offer superior human relevance over immortalized Caco-2 lines. Differentiation takes ~2 weeks versus 3 weeks for Caco-2, with key features including continuous mucus layers and high expression of ADM biomarkers (transporters, metabolic enzymes). Multi-organ MPS systems interconnect gut and liver compartments through fluidic flow, enabling simulation of oral and intravenous dosing. Special co-culture media maintains functionality for 48+ hours. Validation with 7-hydroxycoumarin demonstrated collective metabolism by gut-liver models, proving capability for ADM profiling of compound metabolism across interconnected organs.

In vitro transporter inhibition assays for P-gp and BCRP use two main test systems: the transwell assay (measuring bidirectional permeability across cell monolayers) and the vesicle assay (measuring direct transporter-mediated uptake in membrane vesicles); both systems require qualification to determine optimal conditions, including time courses, kinetic parameters (KM), and IC50/Ki values, with IC50 values typically used for clinical relevance predictions based on FDA and EMA guidelines that compare inhibitor potency against projected clinical concentrations to determine if drug-drug interaction studies are warranted.

This webinar presents a comprehensive framework for evaluating transporter-mediated drug-drug interactions (DDI) in drug discovery programs, covering the fundamental role of transporters (ABC efflux transporters like P-gp and BCRP, and SLC influx transporters like OATPs, OATs, OCTs, and MATEs) in drug disposition, regulatory agency recommendations from FDA, EMA, and PMDA, and a detailed methodology for substrate and inhibition assays using in vitro systems including inside-out membrane vesicles, polarized cell-based bidirectional permeability assays, and transporter-overexpressing cell lines, with practical guidance on selecting appropriate test concentrations and interpreting results to meet regulatory requirements.

Regulatory agencies provide comprehensive guidance for transporter-mediated DDI assessment. FDA requires universal screening for P-gp and BCRP substrates, with additional screening for OATP1B1/1B3 if hepatic elimination exceeds 25% of total clearance, and for OAT1/OAT3/OCT2/MATE1/MATE2K if renal elimination exceeds 25%. EMA adds recommendations for BSEP and MRPs if hepatic elimination is clinically significant. Decision trees guide systematic evaluation: bidirectional transport studies identify substrates, followed by inhibitor testing to confirm efflux mechanisms. For P-gp inhibition, sponsors must demonstrate inhibition potency (Ki or IC50) on known substrates in overexpressing cells, with I_max/IC50 thresholds of ≥0.1 for parenteral and ≥10 for oral administration. For OATP1B1/1B3 inhibition, the R value (inhibition potential at liver inlet) must be ≥1.5 for significant potential.

Drug transporters are membrane-bound proteins that facilitate drug movement across cell membranes, categorized into efflux transporters (ATP-binding cassette superfamily like P-gp and BCRP) and uptake transporters (solute carrier superfamily like OATPs and OCTs), and they play a critical role in drug absorption, distribution, tissue targeting, and elimination; regulatory agencies (FDA, EMA, PMDA) recommend evaluating nine main transporters for DDI risk assessment, with study designs varying by transporter type including transwell assays for efflux transporters and vesicle assays for BSEP and MRP2, requiring careful optimization of test article concentrations, incubation times, and inclusion of appropriate positive controls to accurately assess substrate and inhibitor potential.

Transporters are distributed across key organs: intestine (P-gp, BCRP limit absorption), liver (OATP1B1/1B3 for uptake, bile canaliculi for secretion), kidneys (OCT1/2, OAT1/3 for uptake, P-gp/MRP for secretion), and blood-brain barrier (P-gp, BCRP limit CNS entry). Analysis of 103 approved drugs (2013-2016) revealed 47 were P-gp substrates, 20 were BCRP substrates, and 8 were OATP substrates, with transporters contributing to 46% of clinically relevant DDIs. Tacrolimus clearance exemplifies transporter-mediated DDI: OAT uptake and MRP secretion in kidneys; probenecid prevents nephrotoxicity while ritonavir causes accumulation. In vitro vesicular transport assays use membrane vesicles from transfected cells, enabling assessment of drug candidates as inhibitors or substrates of efflux transporters with radio-labeled substrates, though compounds with high passive permeability pose challenges.